---
layout: minimal-medicine
title: Inotuzumab Ozogamicin
---

# Inotuzumab Ozogamicin
### Generic Name
Inotuzumab Ozogamicin

### Usage

Inotuzumab ozogamicin is a targeted therapy primarily used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).  This means it's used for patients whose ALL has come back after treatment (relapsed) or hasn't responded to initial treatment (refractory). It's a powerful drug typically reserved for patients who have exhausted other treatment options.  While its primary use is in adult ALL, it's crucial to understand that it's not suitable for all cases of ALL, and suitability is determined by a healthcare professional considering the patient's specific circumstances and overall health.

### Dosage

Inotuzumab ozogamicin is administered intravenously (IV).  Dosage is complex and highly individualized, based on the patient's body surface area (BSA, calculated from height and weight), response to treatment, and the presence of any side effects.  Premedication with corticosteroids, antipyretics (fever reducers), and antihistamines is typically recommended before each dose to help minimize potential infusion reactions.

**Adults with relapsed/refractory B-cell precursor ALL:**

* **Cycle 1:**  Usually involves a total dose of 1.8 mg/m² given in three separate infusions on days 1, 8, and 15 of a 21-day cycle. The specific dose for each infusion day varies (0.8mg/m² on day 1, and 0.5mg/m² on days 8 and 15).  The cycle length might be extended to 28 days depending on the patient's response and recovery.
* **Subsequent Cycles:** Dosing in subsequent cycles depends heavily on the patient's response to the first cycle.  If a complete remission (CR) or CR with incomplete hematologic recovery (CRi) is achieved, the dose is usually reduced to a total of 1.5 mg/m² over three infusions in a 28-day cycle. If CR or CRi is not achieved, the higher dose (1.8 mg/m²) is often continued.  Treatment typically continues for up to six cycles or until a complete remission is reached. For patients proceeding to a hematopoietic stem-cell transplant (HSCT), the recommended duration is typically 2 cycles (or 3 if CR/CRi and minimal residual disease negativity are not achieved after 2 cycles).

**Pediatric Dosage:**  The safety and efficacy of inotuzumab ozogamicin have not been established in children.

**Dosage Adjustments:**  Dosage adjustments are necessary based on several factors, including liver and kidney function, and the severity of side effects.  Dose modifications might involve reducing the total dose, decreasing the frequency of infusions, or temporarily interrupting treatment until side effects subside. In cases of severe liver toxicity or veno-occlusive disease (VOD), treatment should be discontinued permanently.


### Side Effects

Inotuzumab ozogamicin can cause a range of side effects, some common and others more serious.  It's crucial to report any concerning symptoms to your doctor immediately.

**Common Side Effects (occurring in more than 10% of patients):**

* Fatigue
* Headache
* Chills
* Nausea
* Abdominal pain
* Diarrhea
* Constipation
* Vomiting
* Decreased appetite
* Thrombocytopenia (low platelet count)
* Neutropenia (low neutrophil count)
* Anemia (low red blood cell count)
* Increased liver enzyme levels (ALT, AST, ALP)
* Infusion-related reactions


**Less Common but Serious Side Effects:**

* Hepatotoxicity (liver damage), including veno-occlusive disease (VOD) – a potentially life-threatening complication.
* Hemorrhage (bleeding)
* Bone marrow suppression
* Tumor lysis syndrome
* QT interval prolongation (changes in heart rhythm)
* Infections (bacterial, fungal, viral)


### How it Works

Inotuzumab ozogamicin is an antibody-drug conjugate (ADC).  It consists of a monoclonal antibody (inotuzumab) that targets CD22, a protein found on the surface of B-cells (a type of white blood cell).  The antibody is linked to a potent cytotoxic agent (calicheamicin), a substance that kills cancer cells.  The drug works by binding to CD22 on the surface of leukemia cells. This triggers the internalization of the ADC, leading to the release of calicheamicin inside the cell.  Calicheamicin then damages the leukemia cell's DNA, causing cell death (apoptosis).


### Precautions

* **Hypersensitivity:** Inotuzumab ozogamicin is contraindicated in patients with known hypersensitivity to the drug or any of its components.
* **Hepatotoxicity:**  There's a significant risk of hepatotoxicity, including VOD.  Liver function tests should be closely monitored.
* **Myelosuppression:**  The drug can suppress bone marrow function, leading to low blood cell counts (anemia, neutropenia, thrombocytopenia).  Regular blood tests are essential.
* **QT Prolongation:** Inotuzumab ozogamicin can prolong the QT interval on an electrocardiogram (ECG), increasing the risk of abnormal heart rhythms.  Patients with pre-existing heart conditions or those taking other medications that prolong the QT interval should be carefully monitored.
* **Pregnancy and Breastfeeding:**  The drug can harm a developing fetus.  Women of reproductive age should use effective contraception during and after treatment.  Breastfeeding should be avoided during and for at least two months after treatment.
* **Drug Interactions:**  Inotuzumab ozogamicin may interact with other medications, particularly those that prolong the QT interval.


### FAQs

* **Q: How long does it take to see results from Inotuzumab Ozogamicin?**  A: The response to treatment varies considerably, but some patients may experience improvement within a few weeks, while others may take longer.  Regular monitoring and assessment are essential.

* **Q: How is Inotuzumab Ozogamicin stored?** A: Refer to the product label for specific storage instructions, but it generally needs to be refrigerated.

* **Q: What should I do if I miss a dose?** A: Consult your doctor immediately.  Do not take a double dose.

* **Q: Are there long-term effects associated with Inotuzumab Ozogamicin?** A: Like all cancer treatments, there's a possibility of long-term side effects.  Regular follow-up appointments are critical for monitoring and managing any potential long-term issues.

* **Q: Can Inotuzumab Ozogamicin be used to prevent ALL?** A: No, Inotuzumab Ozogamicin is a treatment for relapsed or refractory ALL, not a preventative measure.


**Disclaimer:** This information is intended for general knowledge and informational purposes only, and does not constitute medical advice.  Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The specific dosage, administration, and monitoring of Inotuzumab Ozogamicin should be determined and overseen by a qualified healthcare provider.
